Coherent (NASDAQ:COHR) Given New $182.00 Price Target at Benchmark

Share on StockTwits

Coherent (NASDAQ:COHR) had its price target raised by Benchmark from $175.00 to $182.00 in a research report sent to investors on Wednesday, The Fly reports. Benchmark currently has a buy rating on the scientific and technical instruments company’s stock.

COHR has been the topic of several other research reports. BidaskClub lowered shares of Coherent from a buy rating to a hold rating in a report on Thursday, October 24th. TheStreet lowered shares of Coherent from a b- rating to a c+ rating in a report on Wednesday, August 14th. Zacks Investment Research upgraded shares of Coherent from a strong sell rating to a hold rating in a report on Tuesday, October 1st. Finally, ValuEngine lowered shares of Coherent from a buy rating to a hold rating in a report on Monday, October 21st. Eight research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Coherent presently has an average rating of Hold and an average target price of $151.40.

Coherent stock traded down $6.79 during mid-day trading on Wednesday, reaching $160.22. The company had a trading volume of 368,500 shares, compared to its average volume of 346,564. The company has a market capitalization of $3.95 billion, a P/E ratio of 32.76 and a beta of 1.76. The stock’s 50-day simple moving average is $153.94 and its 200-day simple moving average is $141.16. Coherent has a 1 year low of $90.10 and a 1 year high of $173.92. The company has a debt-to-equity ratio of 0.31, a current ratio of 3.97 and a quick ratio of 2.34.

Coherent (NASDAQ:COHR) last posted its earnings results on Tuesday, November 5th. The scientific and technical instruments company reported $0.89 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.96 by ($0.07). The business had revenue of $335.50 million for the quarter, compared to analyst estimates of $329.12 million. Coherent had a net margin of 3.76% and a return on equity of 8.90%. The business’s revenue was down 27.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.22 EPS. On average, equities analysts forecast that Coherent will post 4.57 EPS for the current fiscal year.

Several large investors have recently bought and sold shares of the stock. MUFG Americas Holdings Corp acquired a new position in Coherent in the 3rd quarter worth $25,000. Steward Partners Investment Advisory LLC acquired a new position in Coherent in the 2nd quarter worth $28,000. Cerebellum GP LLC acquired a new position in Coherent in the 2nd quarter worth $48,000. Quadrant Capital Group LLC lifted its holdings in Coherent by 160.6% in the 3rd quarter. Quadrant Capital Group LLC now owns 404 shares of the scientific and technical instruments company’s stock worth $55,000 after buying an additional 249 shares in the last quarter. Finally, Whittier Trust Co. of Nevada Inc. lifted its holdings in Coherent by 724.1% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 478 shares of the scientific and technical instruments company’s stock worth $73,000 after buying an additional 420 shares in the last quarter. Institutional investors and hedge funds own 99.24% of the company’s stock.

Coherent Company Profile

Coherent, Inc provides lasers, laser-based technologies, and laser-based system solutions for a range of scientific, commercial, and industrial applications. It operates through two segments, OEM Laser Sources and Industrial Lasers & Systems. The company designs, manufactures, markets, and services lasers, laser tools, precision optics, and related accessories; and laser measurement and control products.

See Also: The limitations of an equal weight rating

The Fly

Analyst Recommendations for Coherent (NASDAQ:COHR)

Receive News & Ratings for Coherent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherent and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.